Dementia is a term for several diseases that affect memory, thinking, and the ability to perform daily activities. It ranks as the third leading cause of death in Europe and continues to rob people of their memories, independence, relationships, and ultimately, their futures. Alzheimer’s disease (AD) causes between 60-70% of cases of dementia and can be characterised by progressive cognitive decline and memory loss. At Lilly, we understand that people living with AD don’t have time to waste, which is why we’ve remained committed to taking on AD from every angle for the last three decades. Our vision is that in 10 years, timely detection, accurate diagnosis, appropriate treatment and ultimately prevention will be a reality.

The emergence of new investigational medicines presents a unique opportunity to instil hope among those impacted by AD-related dementia and reduce the societal burden associated with the disease. However, in order to unlock the potential of new breakthroughs there is a need to revolutionize our approach to managing these conditions, integrating policy and health system reforms to better serve those living with AD and dementia. To this end, we are proud to support Alzheimer Europe’s novel #DementiaNeedsEU campaign , which encourages policy makers to prioritise dementia and take concrete steps to ensure that people affected by the condition are supported to live as well as they can. Join us and get involved by following #DementiaNeedsEU and #DementiaPledge2024 on social media.